Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon for Sleep Disturbances in Smith-Magenis Syndrome
NCT02231008Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Smith-Magenis syndrome (SMS) comparing Tasimelteon with Placebo (2 arms). Primary endpoints: Daily Diary Sleep Quality (50% worst nights) at 9 weeks and Daily Diary Total Nighttime Sleep Duration (50% worst nights) at 9 weeks. Started Sep 2015; status: completed.
02
Drugs
tasimelteon
03
Conditions
Smith-Magenis syndrome (SMS)
Beyond the preview
Go deeper on NCT02231008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231008.